The reiteration of a Neutral rating and maintenance of a $35 price target by HC Wainwright & Co. suggests that the analyst sees no immediate catalysts that would significantly change the stock's valuation in the short term. This assessment likely reflects a stable outlook for Alkermes, without significant positive or negative changes expected in the near future.